Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

tions, including commencing Phase 3 activities with bremelanotide for FSD, through at least calendar year 2013.

Conference Call / Webcast
Palatin will host a conference call and webcast on May 14, 2013 at 11:00 a.m. Eastern Time to discuss the results of operations and an update on development of bremelanotide for FSD and other corporate developments.  Individuals interested in listening to the conference call live can dial 1-888-427-9419 (domestic) or 1-719-457-2648 (international) pass code 8591699.  The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and webcast replay will be available approximately one hour after the completion of the call.  To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 8591699.  The webcast and telephone replay will be available through May 21, 2013.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.  Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.Forward-looking Statements
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates and market potential for product candidates, are "f
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
3. Palatin Technologies To Present At The 25th Annual ROTH Conference
4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... OAK RIDGE, Tenn., July 24, 2014 -- A novel ... at the Department of Energy,s Oak Ridge National Laboratory ... known for its unusual physical and electrochemical properties. ... examined how oxygen affects the surface of a perovskite ... electronic behavior. The new avenue to understand surface behavior ...
(Date:7/24/2014)... Security forces worldwide rely on sophisticated equipment, trained ... other public areas against terrorist attacks. A revolutionary ... about to make their job much easier. , ... Patolsky of Tel Aviv University ,s School of ... developed by the Herzliya company Tracense, picks up ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
(Date:7/24/2014)... Three companies from the angelMD network ... C Competition. Out of 700 competition entrants, Chiron Health, ... semi-final round. In this round twenty teams are invited ... with mentoring from thought-leaders and medical entrepreneurs from all ... angelMD commitment to the Livestrong vision around the Big ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... Spherix,Incorporated (Nasdaq: SPEX ) reported a net ... The Company,s research and development costs,jumped to $5.9 million ... of,the Company,s Phase 3 clinical trial for Naturlose as ... trial is expected to last at least two years,and ...
... Meets LEEDS Standards for Sustainable Development, PLEASANTON, ... today announced the opening of its new research ... The,building represents the final phase of consolidation of ... which now houses close to 500,employees, including 120 ...
... Ratcliff, the,award-winning architecture, planning and interiors firm, ... care tower,accompanied by a 767-stall parking garage and ... - Walnut Creek Campus. The Thomas J.,and Muriel ... ground will add,230 private and six semi-private rooms, ...
Cached Biology Technology:Spherix Reports 2007 Financial Results 2Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building 2Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building 3Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus 2Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus 3
(Date:7/24/2014)... 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") ... active control Phase 3 study of Zerenex (ferric citrate), ... the treatment of hyperphosphatemia in patients with end-stage renal ... and iRon delivery with FErric CiTrate in EsrD) was ... American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... numbers have decreased by 45% on average over a ... reports a study on the impact of humans on ... enormous benefits invertebrates such as insects, spiders, crustaceans, slugs ... and pest control for crops, decomposition for nutrient cycling, ... in Science and led by UCL, Stanford ...
(Date:7/24/2014)... the product of 3.5 billion years of evolutionary trial ... life. But it may be reaching a tipping point. ... analysis of data published in Science , an ... decline of animals is contributing to what appears to ... biological extinction event. , Since 1500, more than 320 ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
... research in France on patients diagnosed with cryptococcosis ... patients infected by HIV and who are profoundly ... 5 2007 in PLoS Medicine, uncovers parameters associated ... sex and the infecting serotype. In light of ...
... In a venture once thought to lie outside the ... Beth Israel Deaconess Medical Center have captured and sequenced ... Tyrannosaurus rex. The protein fragments—seven in all—appear to most ... present day chickens, lending support to a recent and ...
... international consortium of researchers has published the genome sequence ... the chimpanzee and human genomes. Published April 13 in ... reveals that the three primate species share about 93 ... among their genes. , In its paper, the Rhesus ...
Cached Biology News:New recommendations against a major opportunistic infection -- cryptococcosis 2New recommendations against a major opportunistic infection -- cryptococcosis 3Protein fragments sequenced in 68 million-year-old Tyrannosaurus rex 2Protein fragments sequenced in 68 million-year-old Tyrannosaurus rex 3Protein fragments sequenced in 68 million-year-old Tyrannosaurus rex 4Analysis of rhesus monkey genome uncovers genetic differences with humans, chimps 2Analysis of rhesus monkey genome uncovers genetic differences with humans, chimps 3
... Useful as a positive control for ... to chromatin in vivo is a crucial ... extent of crosslinking is probably the most ... subsequent immunoprecipitation step should be taken into ...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
Rab GDP dissociation inhibitor beta...
Biology Products: